Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has issued an announcement.
Sihuan Pharmaceutical Holdings Group has announced a strategic partnership with dProtein Pharmaceutical Biotechnology to establish an AI-driven R&D company focused on developing novel medical aesthetic products. This collaboration aims to leverage AI technology to innovate high-end medical aesthetic raw materials, reduce costs, and enhance efficiency, thereby strengthening Sihuan’s competitive position in the medical aesthetics industry. The initiative is expected to address unmet market needs and boost the company’s long-term growth and market value.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group, founded in 2001 and listed on the Hong Kong Stock Exchange in 2010, is an international company specializing in medical aesthetics and pharmaceuticals. The company is driven by innovation, boasting a leading research and development platform, a diverse global product pipeline, and efficient production and sales systems. Sihuan aims to become a leading entity in China’s medical aesthetics and biopharmaceutical sectors.
YTD Price Performance: 121.21%
Average Trading Volume: 112,034,374
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.62B
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.